Industry finds flaws Indian per-capita income-linked price approach for patented drugs
This article was originally published in Scrip
Executive Summary
An Indian government panel's suggestion to set prices of patented medicines using a per capita income-linked reference pricing model has sparked criticism from several quarters of the pharmaceutical industry, which believes that the approach is flawed and that a suitable access model should be considered instead.